From the Division of Radiology (A.A., P.M., T.D.P., P.-A.P., M.B.), Department of Imaging and Medical Informatics.
Division of Clinical Pathology (M.P.), Department of Laboratory and Genetics, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
AJNR Am J Neuroradiol. 2018 Apr;39(4):748-755. doi: 10.3174/ajnr.A5548. Epub 2018 Feb 15.
Although diffusion-weighted imaging combined with morphologic MRI (DWIMRI) is used to detect posttreatment recurrent and second primary head and neck squamous cell carcinoma, the diagnostic criteria used so far have not been clarified. We hypothesized that precise MRI criteria based on signal intensity patterns on T2 and contrast-enhanced T1 complement DWI and therefore improve the diagnostic performance of DWIMRI.
We analyzed 1.5T MRI examinations of 100 consecutive patients treated with radiation therapy with or without additional surgery for head and neck squamous cell carcinoma. MRI examinations included morphologic sequences and DWI (=0 and =1000 s/mm). Histology and follow-up served as the standard of reference. Two experienced readers, blinded to clinical/histologic/follow-up data, evaluated images according to clearly defined criteria for the diagnosis of recurrent head and neck squamous cell carcinoma/second primary head and neck squamous cell carcinoma occurring after treatment, post-radiation therapy inflammatory edema, and late fibrosis. DWI analysis included qualitative (visual) and quantitative evaluation with an ADC threshold.
Recurrent head and neck squamous cell carcinoma/second primary head and neck squamous cell carcinoma occurring after treatment was present in 36 patients, whereas 64 patients had post-radiation therapy lesions only. The Cohen κ for differentiating tumor from post-radiation therapy lesions with MRI and qualitative DWIMRI was 0.822 and 0.881, respectively. Mean ADCmean in recurrent head and neck squamous cell carcinoma/second primary head and neck squamous cell carcinoma occurring after treatment (1.097 ± 0.295 × 10 mm/s) was significantly lower ( < .05) than in post-radiation therapy inflammatory edema (1.754 ± 0.343 × 10 mm/s); however, it was similar to that in late fibrosis (0.987 ± 0.264 × 10 mm/s, > .05). Although ADCs were similar in tumors and late fibrosis, morphologic MRI criteria facilitated distinction between the 2 conditions. The sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios (95% CI) of DWIMRI with ADCmean < 1.22 × 10 mm/s and precise MRI criteria were 92.1% (83.5-100.0), 95.4% (90.3-100.0), 92.1% (83.5-100.0), 95.4% (90.2-100.0), 19.9 (6.58-60.5), and 0.08 (0.03-0.24), respectively, indicating a good diagnostic performance to rule in and rule out disease.
Adding precise morphologic MRI criteria to quantitative DWI enables reproducible and accurate detection of recurrent head and neck squamous cell carcinoma/second primary head and neck squamous cell carcinoma occurring after treatment.
弥散加权成像结合形态学 MRI(DWIMRI)用于检测头颈部鳞癌治疗后复发和第二原发灶,但目前尚未明确其诊断标准。我们假设基于 T2 和增强 T1 上信号强度模式的精确 MRI 标准可以补充 DWI,从而提高 DWIMRI 的诊断性能。
我们分析了 100 例接受头颈部鳞癌放化疗或联合手术治疗患者的 1.5T MRI 检查。MRI 检查包括形态序列和 DWI(=0 和=1000 s/mm)。以组织学和随访为参考标准。两名有经验的阅片者在不了解临床/组织学/随访数据的情况下,根据明确的治疗后复发头颈部鳞癌/第二原发灶头颈部鳞癌、放疗后炎症性水肿和晚期纤维化的诊断标准,对图像进行评估。DWI 分析包括定性(视觉)和 ADC 阈值的定量评估。
36 例患者存在治疗后复发头颈部鳞癌/第二原发灶头颈部鳞癌,64 例患者仅有放疗后病变。MRI 和定性 DWIMRI 鉴别肿瘤与放疗后病变的 Cohen κ 值分别为 0.822 和 0.881。治疗后复发头颈部鳞癌/第二原发灶头颈部鳞癌的平均 ADCmean(1.097±0.295×10mm/s)显著低于放疗后炎症性水肿(1.754±0.343×10mm/s)(<0.05),但与晚期纤维化相似(0.987±0.264×10mm/s,>0.05)。虽然肿瘤与晚期纤维化的 ADC 值相似,但形态学 MRI 标准有助于区分这两种情况。ADCmean<1.22×10mm/s 结合精确 MRI 标准的 DWIMRI 的灵敏度、特异性、阳性和阴性预测值、阳性和阴性似然比(95%CI)分别为 92.1%(83.5-100.0)、95.4%(90.3-100.0)、92.1%(83.5-100.0)、95.4%(90.2-100.0)、19.9(6.58-60.5)和 0.08(0.03-0.24),表明该方法具有良好的诊断效能,可用于疾病的确诊和排除。
定量 DWI 结合精确形态学 MRI 标准可重复性好、准确性高,有助于检测治疗后复发头颈部鳞癌/第二原发灶头颈部鳞癌。